You have permission to edit this article.

AstraZeneca asks FDA to authorize COVID antibody treatment

  • Updated
  • 0

LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca has asked the U.S. Food and Drug Administration to authorize the emergency use of an antibody treatment to prevent COVID-19.

The company said Tuesday that the treatment would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention.

coronavirus - dark blue mgn.jpg

The FDA has authorized three other antibody drugs already. Two of them can be given after a possible COVID-19 exposure to try and head off symptoms.

AstraZeneca’s drug would instead be given as a preventive measure in people who have increased vulnerability to the virus and whose immune systems don’t respond well to vaccines. 

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.